These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 31647098)

  • 1. Histone lysine demethylase KDM4B regulates the alternative splicing of the androgen receptor in response to androgen deprivation.
    Duan L; Chen Z; Lu J; Liang Y; Wang M; Roggero CM; Zhang QJ; Gao J; Fang Y; Cao J; Lu J; Zhao H; Dang A; Pong RC; Hernandez E; Chang CM; Hoang DT; Ahn JM; Xiao G; Wang RT; Yu KJ; Kapur P; Rizo J; Hsieh JT; Luo J; Liu ZP
    Nucleic Acids Res; 2019 Dec; 47(22):11623-11636. PubMed ID: 31647098
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting KDM4B that coactivates c-Myc-regulated metabolism to suppress tumor growth in castration-resistant prostate cancer.
    Wu MJ; Chen CJ; Lin TY; Liu YY; Tseng LL; Cheng ML; Chuu CP; Tsai HK; Kuo WL; Kung HJ; Wang WC
    Theranostics; 2021; 11(16):7779-7796. PubMed ID: 34335964
    [No Abstract]   [Full Text] [Related]  

  • 3. Histone demethylase JMJD1A promotes alternative splicing of AR variant 7 (AR-V7) in prostate cancer cells.
    Fan L; Zhang F; Xu S; Cui X; Hussain A; Fazli L; Gleave M; Dong X; Qi J
    Proc Natl Acad Sci U S A; 2018 May; 115(20):E4584-E4593. PubMed ID: 29712835
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Upregulated KDM4B promotes prostate cancer cell proliferation by activating autophagy.
    Sha J; Han Q; Chi C; Zhu Y; Pan J; Dong B; Huang Y; Xia W; Xue W
    J Cell Physiol; 2020 Mar; 235(3):2129-2138. PubMed ID: 31468537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diverse AR-V7 cistromes in castration-resistant prostate cancer are governed by HoxB13.
    Chen Z; Wu D; Thomas-Ahner JM; Lu C; Zhao P; Zhang Q; Geraghty C; Yan PS; Hankey W; Sunkel B; Cheng X; Antonarakis ES; Wang QE; Liu Z; Huang TH; Jin VX; Clinton SK; Luo J; Huang J; Wang Q
    Proc Natl Acad Sci U S A; 2018 Jun; 115(26):6810-6815. PubMed ID: 29844167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Melatonin Inhibits Androgen Receptor Splice Variant-7 (AR-V7)-Induced Nuclear Factor-Kappa B (NF-κB) Activation and NF-κB Activator-Induced AR-V7 Expression in Prostate Cancer Cells: Potential Implications for the Use of Melatonin in Castration-Resistant Prostate Cancer (CRPC) Therapy.
    Liu VWS; Yau WL; Tam CW; Yao KM; Shiu SYW
    Int J Mol Sci; 2017 May; 18(6):. PubMed ID: 28561752
    [TBL] [Abstract][Full Text] [Related]  

  • 7. JMJD6 Is a Druggable Oxygenase That Regulates AR-V7 Expression in Prostate Cancer.
    Paschalis A; Welti J; Neeb AJ; Yuan W; Figueiredo I; Pereira R; Ferreira A; Riisnaes R; Rodrigues DN; Jiménez-Vacas JM; Kim S; Uo T; Micco PD; Tumber A; Islam MS; Moesser MA; Abboud M; Kawamura A; Gurel B; Christova R; Gil VS; Buroni L; Crespo M; Miranda S; Lambros MB; Carreira S; Tunariu N; Alimonti A; Al-Lazikani B; Schofield CJ; Plymate SR; Sharp A; de Bono JS;
    Cancer Res; 2021 Feb; 81(4):1087-1100. PubMed ID: 33822745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ZFX Mediates Non-canonical Oncogenic Functions of the Androgen Receptor Splice Variant 7 in Castrate-Resistant Prostate Cancer.
    Cai L; Tsai YH; Wang P; Wang J; Li D; Fan H; Zhao Y; Bareja R; Lu R; Wilson EM; Sboner A; Whang YE; Zheng D; Parker JS; Earp HS; Wang GG
    Mol Cell; 2018 Oct; 72(2):341-354.e6. PubMed ID: 30270106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DBC1 promotes castration-resistant prostate cancer by positively regulating DNA binding and stability of AR-V7.
    Moon SJ; Jeong BC; Kim HJ; Lim JE; Kwon GY; Kim JH
    Oncogene; 2018 Mar; 37(10):1326-1339. PubMed ID: 29249800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Androgen receptor and its splice variant, AR-V7, differentially regulate FOXA1 sensitive genes in LNCaP prostate cancer cells.
    Krause WC; Shafi AA; Nakka M; Weigel NL
    Int J Biochem Cell Biol; 2014 Sep; 54():49-59. PubMed ID: 25008967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Androgen receptor splice variants drive castration-resistant prostate cancer metastasis by activating distinct transcriptional programs.
    Han D; Labaf M; Zhao Y; Owiredu J; Zhang S; Patel K; Venkataramani K; Steinfeld JS; Han W; Li M; Liu M; Wang Z; Besschetnova A; Patalano S; Mulhearn MJ; Macoska JA; Yuan X; Balk SP; Nelson PS; Plymate SR; Gao S; Siegfried KR; Liu R; Stangis MM; Foxa G; Czernik PJ; Williams BO; Zarringhalam K; Li X; Cai C
    J Clin Invest; 2024 Apr; 134(11):. PubMed ID: 38687617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Constitutively active androgen receptor splice variants AR-V3, AR-V7 and AR-V9 are co-expressed in castration-resistant prostate cancer metastases.
    Kallio HML; Hieta R; Latonen L; Brofeldt A; Annala M; Kivinummi K; Tammela TL; Nykter M; Isaacs WB; Lilja HG; Bova GS; Visakorpi T
    Br J Cancer; 2018 Aug; 119(3):347-356. PubMed ID: 29988112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic targeting of histone lysine demethylase KDM4B blocks the growth of castration-resistant prostate cancer.
    Duan L; Chen YA; Liang Y; Chen Z; Lu J; Fang Y; Cao J; Lu J; Zhao H; Pong RC; Hernandez E; Kapur P; Tran TAT; Smith T; Martinez ED; Ahn JM; Hsieh JT; Luo JH; Liu ZP
    Biomed Pharmacother; 2023 Feb; 158():114077. PubMed ID: 36495660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Androgen Receptor Variant AR-V9 Is Coexpressed with AR-V7 in Prostate Cancer Metastases and Predicts Abiraterone Resistance.
    Kohli M; Ho Y; Hillman DW; Van Etten JL; Henzler C; Yang R; Sperger JM; Li Y; Tseng E; Hon T; Clark T; Tan W; Carlson RE; Wang L; Sicotte H; Thai H; Jimenez R; Huang H; Vedell PT; Eckloff BW; Quevedo JF; Pitot HC; Costello BA; Jen J; Wieben ED; Silverstein KAT; Lang JM; Wang L; Dehm SM
    Clin Cancer Res; 2017 Aug; 23(16):4704-4715. PubMed ID: 28473535
    [No Abstract]   [Full Text] [Related]  

  • 15. Targeting AR Variant-Coactivator Interactions to Exploit Prostate Cancer Vulnerabilities.
    Magani F; Peacock SO; Rice MA; Martinez MJ; Greene AM; Magani PS; Lyles R; Weitz JR; Burnstein KL
    Mol Cancer Res; 2017 Nov; 15(11):1469-1480. PubMed ID: 28811363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer.
    Sharp A; Coleman I; Yuan W; Sprenger C; Dolling D; Rodrigues DN; Russo JW; Figueiredo I; Bertan C; Seed G; Riisnaes R; Uo T; Neeb A; Welti J; Morrissey C; Carreira S; Luo J; Nelson PS; Balk SP; True LD; de Bono JS; Plymate SR
    J Clin Invest; 2019 Jan; 129(1):192-208. PubMed ID: 30334814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alternative splicing in prostate cancer.
    Paschalis A; Sharp A; Welti JC; Neeb A; Raj GV; Luo J; Plymate SR; de Bono JS
    Nat Rev Clin Oncol; 2018 Nov; 15(11):663-675. PubMed ID: 30135575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Suppression of prostate tumor cell survival by antisense oligonucleotide-mediated inhibition of AR-V7 mRNA synthesis.
    Luna Velez MV; Verhaegh GW; Smit F; Sedelaar JPM; Schalken JA
    Oncogene; 2019 May; 38(19):3696-3709. PubMed ID: 30664691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the KDM4B-AR-c-Myc axis promotes sensitivity to androgen receptor-targeted therapy in advanced prostate cancer.
    Tang DE; Dai Y; He JX; Lin LW; Leng QX; Geng XY; Fu DX; Jiang HW; Xu SH
    J Pathol; 2020 Oct; 252(2):101-113. PubMed ID: 32617978
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analytical Validation and Clinical Qualification of a New Immunohistochemical Assay for Androgen Receptor Splice Variant-7 Protein Expression in Metastatic Castration-resistant Prostate Cancer.
    Welti J; Rodrigues DN; Sharp A; Sun S; Lorente D; Riisnaes R; Figueiredo I; Zafeiriou Z; Rescigno P; de Bono JS; Plymate SR
    Eur Urol; 2016 Oct; 70(4):599-608. PubMed ID: 27117751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.